Concepedia

Daniel L. Menezes

DL

Statistics

Publications

24

Citations

2K

H-Index

18

Active since

2002

Affiliations

Bristol-Myers Squibb (United States)(Current)

Assistance Publique – Hôpitaux de Paris

The University of Texas MD Anderson Cancer Center

Université Paris Cité

University of Kansas Medical Center

Daniel L. Menezes is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, medicine, and molecular oncology.

Publications per year

2002–2024

24

Publications

24

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 529 citations

, , +13

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Matthew T. Burger, Sabina Pecchi, Allan S. Wagman et al. · ACS Medicinal Chemistry Letters · 2011 · 251 citations · Full text

, , +13

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study

Lorenzo Falchi, Helen Ma, Sandra E. Klein et al. · Blood · 2020 · 185 citations · Full text

, , +4

<i>In vivo</i> Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Sang Hoon Lee, Daniel L. Menezes, Jayesh Vora et al. · Clinical Cancer Research · 2005 · 173 citations

, , +17

Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study

Owen A. O’Connor, Lorenzo Falchi, Jennifer Kimberly Lue et al. · Blood · 2019 · 128 citations · Full text

, , +4

1–5 of 24